PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Bayer expands women’s health pipeline with KaNDy acquisition

Bayer has announced plans to acquire UK-based biotech company KaNDy Therapeutics, in a move to expand its drug development pipeline in women’s healthcare.

This includes KaNDy’s investigational compound NT-814, which recently completed a Phase IIb study which showed positive findings for the treatment of moderate-to-severe vasomotor symptoms due to the menopause.

A Phase III study is expected to begin in 2021, and if approved, the drug could generate peak sales of more than €1bn globally, according to Bayer.

Under the terms of the deal, Bayer will make an upfront payment of $425m, as well as potential milestone payments of up to $450m until launch followed by potential additional triple digit million sales milestone payments.

The KaNDy acquisition is the latest in a string of deals made by Bayer to expand its reach in women’s healthcare. This includes a collaboration agreement inked earlier this year with Evotec, to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (PCOS).

In January 2020, Bater also signed an exclusive license agreement with US-based Daré Bioscience, focused on its investigational, hormone-free, monthly vaginal contraceptive currently in clinical development for the prevention of pregnancy.

“As a leader in Women’s Health, Bayer is focused on providing new options for women and their healthcare needs,” said Dr. Sebastian Guth, Bayer’s President of Pharmaceuticals, Americas Region.

“This acquisition is another testament to our commitment to the health of women, which not only broadens our pipeline, but has the potential, if approved, to deliver a new treatment option that could have a meaningful impact on women’s lives,” he added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026